Cancer risk among patients with myotonic muscular dystrophy

JAMA

Volumn 306, Issue 22, 2011, Pages 2480-2486

  Gadalla, Shahinaz M ^a   Lund, Marie ^b   Pfeiffer, Ruth M ^a   Gørtz, Sanne ^b   Mueller, Christine M ^a   Moxley III, Richard T ^c   Kristinsson, Sigurdur Y ^d   Björkholm, Magnus ^d   Shebl, Fatma M ^a   Hilbert, James E ^c   Landgren, Ola ^a   Wohlfahrt, Jan ^b   Melbye, Mads ^b   Greene, Mark H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b STATENS SERUM INSTITUT   (Denmark)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; BRAIN CANCER; CANCER INCIDENCE; CANCER RISK; CHILD; COHORT ANALYSIS; COLON CANCER; DENMARK; ENDOMETRIUM CANCER; FEMALE; GENITAL TRACT TUMOR; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MYOTONIC DYSTROPHY; OVARY CANCER; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCHOOL CHILD; SEX DIFFERENCE; SWEDEN;

EID: 83455235044     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.1796     Document Type: Article

References (41)

1. Harper PS. Myotonic Dystrophy. 3rd ed. Philadelphia, PA: WB Saunders; 2001.
2. Brook JD, McCurrach ME, Harley HG, et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family member. Cell. 1992;69(2):385.
3. Fu YH, Pizzuti A, Fenwick RG Jr, et al. An unstable triplet repeat in a gene related to myotonic muscular dystrophy. Science. 1992;255(5049):1256-1258.
4. Mahadevan M, Tsilfidis C, Sabourin L, et al. Myotonic dystrophy mutation: an unstable CTG repeat in the 3′ untranslated region of the gene. Science. 1992;255(5049):1253-1255.
5. Ranum LP, Day JW. Myotonic dystrophy: clinical and molecular parallels between myotonic dystrophy type 1 and type 2. Curr Neurol Neurosci Rep. 2002;2(5):465-470.
6. Liquori CL, Ricker K, Moseley ML, et al. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science. 2001;293(5531):864-867. (Pubitemid 32743976)
7. Suominen T, Bachinski LL, Auvinen S, et al. Population frequency of myotonic dystrophy: higher than expected frequency of myotonic dystrophy type 2 (DM2) mutation in Finland. Eur J Hum Genet. 2011;19(7):776-782.
8. de Die-Smulders CE, Höweler CJ, Thijs C, et al. Age and causes of death in adult-onset myotonic dystrophy. Brain. 1998;121(pt 8):1557-1563. (Pubitemid 28349907)
9. Mathieu J, Allard P, Potvin L, Prévost C, Bégin P. A 10-year study of mortality in a cohort of patients with myotonic dystrophy. Neurology. 1999;52(8):1658-1662. (Pubitemid 29220644)
10. Mankodi A, Urbinati CR, Yuan QP, et al. Muscleblind localizes to nuclear foci of aberrant RNA in myotonic dystrophy types 1 and 2. Hum Mol Genet. 2001;10(19):2165-2170. (Pubitemid 32998828)
11. Wheeler TM, Thornton CA. Myotonic dystrophy: RNA-mediated muscle disease. Curr Opin Neurol. 2007;20(5):572-576. (Pubitemid 47462288)
12. Kanadia RN, Johnstone KA, Mankodi A, et al. A muscleblind knockout model for myotonic dystrophy. Science. 2003;302(5652):1978-1980. (Pubitemid 37523508)
13. Mueller CM, Hilbert JE, Martens W, Thornton CA, Moxley RT III, Greene MH. Hypothesis: neoplasms in myotonic dystrophy. Cancer Causes Control. 2009;20(10):2009-2020.
14. Zemtsov A. Association between basal, squamous cell carcinomas, dysplastic nevi and myotonic muscular dystrophy indicates an important role of RNA-binding proteins in development of human skin cancer. Arch Dermatol Res. 2010;302(3):169-170.
15. Itin PH, Laeng RH. Multiple pigmented basalioma of the scalp in a patient with Curschmann-Steinert myotonia dystrophica: confirmation of a rare symptom constellation [in German]. Hautarzt. 2001;52(3):244-246. (Pubitemid 32217342)
16. Goolamali SI, Edmonds EV, Francis N, Bunker CB. Myotonic dystrophy and basal cell carcinomas: coincidence or true association? Clin Exp Dermatol. 2009;34(7):e370.
17. Azurdia RM, Verbov JL. Myotonic dystrophy and basal cell carcinoma: a true association? Br J Dermatol. 1999;141(5):941-942.
18. Anonymous. Patientregistret 1987-1996: Kvalitet och innehåll [Swedish]. Stockholm, Sweden: EpC, National Board of Health and Welfare; 1998.
19. Nilsson AC, Spetz CL, Carsjö K, Nightingale R, Smedby A. Reliability of the hospital registry: the diagnostic data are better than their reputation [in Swedish]. Lakartidningen. 1994;91(7):598-605.
20. Andersen TF, Madsen M, Jørgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register: a valuable source of data for modern health sciences. Dan Med Bull. 1999;46(3):263-268. (Pubitemid 29299976)
21. Mattsson B, Wallgren A. Completeness of the Swedish Cancer Register: non-notified cancer cases recorded on death certificates in 1978. Acta Radiol Oncol. 1984;23(5):305-313. (Pubitemid 15028463)
22. Turesson I, Linet MS, Björkholm M, et al. Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964-2003. Int J Cancer. 2007;121(10):2260-2266. (Pubitemid 47585607)
23. Storm HH, Michelsen EV, Clemmensen IH, Pihl J. The Danish Cancer Registry: history, content, quality and use. Dan Med Bull. 1997;44(5):535-539.
24. Survey of Nordic Cancer Registries [2000]. Danish Cancer Society. http://www.ncu.nu/ancr/pdf/survey.pdf. Accessed November 15, 2011.
25. Engholm G, Ferlay J, Christensen N, et al. NORDCAN: a Nordic tool for cancer information, planning, quality control and research. Acta Oncol. 2010;49(5):725-736.
26. Greenland S, Rothman KJ. Fundamentals of epidemiology data analysis. In: Rothman KJ, Greenland S, Lash TL, eds. Modern Epidemiology. 3rd ed. Philadelphia, PD: Lippincott Williams & Wilkins; 2008:213-237.
27. Panzer S, Kuhl DP, Caskey CT. Unstable triplet repeat sequences: a source of cancer mutations? Stem Cells. 1995;13(2):146-157.
28. Lukong KE, Chang KW, Khandjian EW, Richard S. RNA-binding proteins in human genetic disease. Trends Genet. 2008;24(8):416-425.
29. Lahiry P, Torkamani A, Schork NJ, Hegele RA. Kinase mutations in human disease: interpreting genotype-phenotype relationships. Nat Rev Genet. 2010;11(1):60-74.
30. Sund R, Pukkala E, Patja K. Cancer incidence among persons with fragile X syndrome in Finland: a population-based study. J Intellect Disabil Res. 2009;53(1):85-90.
31. Sørensen SA, Fenger K, Olsen JH. Significantly lower incidence of cancer among patients with Huntington disease: an apoptotic effect of an expanded polyglutamine tract? Cancer. 1999;86(7):1342-1346. (Pubitemid 29447021)
32. Brouwer JR, Willemsen R, Oostra BA. Microsatellite repeat instability and neurological disease. Bioessays. 2009;31(1):71-83.
33. Osanai R, Kinoshita M, Hirose K, Homma T, Kawabata I. CTG triplet repeat expansion in a laryngeal carcinoma from a patient with myotonic dystrophy. Muscle Nerve. 2000;23(5):804-806. (Pubitemid 30256613)
34. Akiyama M, Yuza Y, Yokokawa Y, Yokoi K, Ariga M, Eto Y. Differences in CTG triplet repeat expansion in leukemic cells and normal lymphocytes from a 14-year-old female with congenital myotonic dystrophy. Pediatr Blood Cancer. 2008;51(4):563-565.
35. Thornton CA, Wymer JP, Simmons Z, McClain C, Moxley RT III. Expansion of the myotonic dystrophy CTG repeat reduces expression of the flanking DMAHP gene. Nat Genet. 1997;16(4):407-409. (Pubitemid 27323311)
36. Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, Boland CR. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet. 2009;76(1):1-18.
37. Goellner GM, Tester D, Thibodeau S, et al. Different mechanisms underlie DNA instability in Huntington disease and colorectal cancer.Am J Hum Genet. 1997;60(4):879-890. (Pubitemid 27146496)
38. Wöhrle D, Kennerknecht I, Wolf M, Enders H, Schwemmle S, Steinbach P. Heterogeneity of DM kinase repeat expansion in different fetal tissues and further expansion during cell proliferation in vitro: evidence for a casual involvement of methyl-directed DNA mismatch repair in triplet repeat stability. Hum Mol Genet. 1995;4(7):1147-1153.
39. Foiry L, Dong L, Savouret C, et al. Msh3 is a limiting factor in the formation of intergenerational CTG expansions in DM1 transgenic mice. Hum Genet. 2006;119(5):520-526.
40. Tomé S, Holt I, Edelmann W, et al. MSH2 ATPase domain mutation affects CTG*CAG repeat instability in transgenicmice. PLoS Genet. 2009;5(5):e1000482.
41. van den Broek WJ, Nelen MR, Wansink DG, et al. Somatic expansion behaviour of the (CTG)n repeat in myotonic dystrophy knock-in mice is differentially affected by Msh3 and Msh6 mismatch-repair proteins. Hum Mol Genet. 2002;11(2):191-198.